{"disease":{"id":"hiv-associated-tuberculosis","name":"hiv associated tuberculosis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05630872","title":"Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}